MIRA
MIRA Pharmaceuticals, Inc.
Price Chart
Latest Quote
$0.95
+0.00 (+0.26%)
Current Price
| Previous Close | $0.95 |
| Open | $0.95 |
| Day High | $0.97 |
| Day Low | $0.95 |
| Volume | 18,667 |
Stock Information
| Shares Outstanding | 42.02M |
| Cash Equivalents | $9.41M |
| Net Income | $-31.37M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $38.26M |
| EPS (TTM) | $-1.27 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $30.68M |
| Income | $-31.37M |
| Book/sh | $0.22 |
| Cash/sh | $0.22 |
Financial Ratios
| Quick Ratio | 81.97 |
| Current Ratio | 82.16 |
Returns & Margins
| ROA | -112.66% |
| ROE | -184.32% |
Ownership
| Insider Ownership | 16.71% |
| Institutional Ownership | 5.03% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.22 |
| P/B | 4.10 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.00 |
| SMA50 | $1.01 |
| SMA200 | $1.26 |
| RSI | 33.49 |
| ATR | 0.0422 |
| Shares Float | 35.03M |
| Short Float | 0.95% |
| Short Ratio | 2.73 |
| Volatility | 1.44 |
| Rel Volume | 0.42 |
Performance History
| Week | -4.17% |
| Month | -8.23% |
| Quarter | -13.30% |
| 6 Months | -44.15% |
| YTD | -38.90% |
| Year | -21.85% |
| 10 Years | -87.73% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.91 | 57,142 |
| 2026-06-23 | $0.95 | 21,600 |
| 2026-06-22 | $0.95 | 126,700 |
| 2026-06-18 | $0.95 | 69,700 |
| 2026-06-17 | $0.98 | 81,700 |
| 2026-06-16 | $0.95 | 136,700 |
| 2026-06-15 | $0.93 | 84,200 |
| 2026-06-12 | $0.94 | 123,100 |
| 2026-06-11 | $0.96 | 53,500 |
| 2026-06-10 | $0.98 | 51,800 |
| 2026-06-09 | $0.98 | 103,600 |
| 2026-06-08 | $1.00 | 73,800 |
| 2026-06-05 | $1.00 | 190,200 |
| 2026-06-04 | $1.06 | 159,100 |
| 2026-06-03 | $1.01 | 97,700 |
| 2026-06-02 | $1.04 | 119,900 |
| 2026-06-01 | $1.05 | 88,000 |
| 2026-05-29 | $1.06 | 76,900 |
| 2026-05-28 | $1.08 | 271,000 |
| 2026-05-27 | $1.15 | 709,300 |
| 2026-05-26 | $0.97 | 68,900 |
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
đ° Latest News
Tapestry patents AI data analytics tech
Retail Dive âĸ 2026-05-19T12:20:00Z
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive âĸ 2026-02-08T20:50:23ZSector Update: Health Care Stocks Softer Late Afternoon
MT Newswires âĸ 2025-10-16T19:51:38ZTop Premarket Gainers
MT Newswires âĸ 2025-07-03T12:05:12ZEXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study
Benzinga âĸ 2025-06-30T11:20:42Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $10,493,112 | $8,018,328 | $8,526,049 | $7,047,940 |
| Other Income Expense | $-48,284 | - | - | - |
| Other Non Operating Income Expenses | $-13,072 | - | - | - |
| Net Non Operating Interest Income Expense | $98,911 | $165,669 | $-3,456,294 | $-10,250 |
| Operating Expense | $10,493,112 | $8,018,328 | $8,526,049 | $7,047,940 |
| General And Administrative Expense | $8,773,329 | $4,712,753 | $6,499,537 | $2,992,125 |
| Total Other Finance Cost | - | $-165,669 | $3,456,294 | - |
| Interest Expense | - | - | $3,456,294 | $10,250 |
| Interest Expense Non Operating | - | - | $3,456,294 | $10,250 |
| Other Operating Expenses | - | - | $453,550 | $1,704,350 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-10,442,485 | $-7,852,659 | $-11,982,343 | $-7,058,190 |
| Net Interest Income | $98,911 | $165,669 | $-3,456,294 | $-10,250 |
| Interest Income | $98,911 | $165,669 | - | - |
| Normalized Income | $-10,407,273 | $-7,852,659 | $-11,982,343 | $-7,058,190 |
| Net Income From Continuing And Discontinued Operation | $-10,442,485 | $-7,852,659 | $-11,982,343 | $-7,058,190 |
| Net Income Common Stockholders | $-31,999,306 | $-7,852,659 | $-11,982,343 | $-7,058,190 |
| Net Income | $-10,442,485 | $-7,852,659 | $-11,982,343 | $-7,058,190 |
| Net Income Including Noncontrolling Interests | $-10,442,485 | $-7,852,659 | $-11,982,343 | $-7,058,190 |
| Net Income Continuous Operations | $-10,442,485 | $-7,852,659 | $-11,982,343 | $-7,058,190 |
| Pretax Income | $-10,442,485 | $-7,852,659 | $-11,982,343 | $-7,058,190 |
| Interest Income Non Operating | $98,911 | $165,669 | - | - |
| Operating Income | $-10,493,112 | $-8,018,328 | $-8,526,049 | $-7,047,940 |
| Per Share | ||||
| Diluted EPS | $-1.35 | $-0.51 | $-0.85 | $-0.40 |
| Basic EPS | $-1.35 | $-0.51 | $-0.85 | $-0.40 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-10,457,900 | $-8,018,328 | $-8,526,049 | $-7,047,940 |
| Total Unusual Items | $-35,212 | - | - | - |
| Total Unusual Items Excluding Goodwill | $-35,212 | - | - | - |
| EBITDA (Bullshit earnings) | $-10,493,112 | $-8,018,328 | $-8,526,049 | $-7,047,940 |
| EBIT | $-10,493,112 | $-8,018,328 | $-8,526,049 | $-7,047,940 |
| Diluted Average Shares | $23,694,333 | $15,444,149 | $13,924,619 | $17,750,667 |
| Basic Average Shares | $23,694,333 | $15,444,149 | $13,924,619 | $17,750,667 |
| Diluted NI Availto Com Stockholders | $-31,999,306 | $-7,852,659 | $-11,982,343 | $-7,058,190 |
| Otherunder Preferred Stock Dividend | $21,556,821 | $0 | - | - |
| Gain On Sale Of Security | $-35,212 | - | - | - |
| Research And Development | $1,719,783 | $3,305,575 | $1,572,962 | $2,351,465 |
| Selling General And Administration | $8,773,329 | $4,712,753 | $6,499,537 | $2,992,125 |
| Other Gand A | $8,773,329 | $4,712,753 | $6,499,537 | $2,992,125 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $10,391,537 | $2,199,750 | $4,374,346 | $-596,232 |
| Total Assets | $11,093,605 | $2,923,099 | $4,932,443 | $858,074 |
| Total Non Current Assets | $35,439 | $35,439 | $74,213 | $363,669 |
| Non Current Accounts Receivable | $35,439 | $35,439 | $69,152 | - |
| Current Assets | $11,058,166 | $2,887,660 | $4,858,230 | $494,405 |
| Prepaid Assets | $28,146 | $54,729 | $243,802 | $0 |
| Cash Cash Equivalents And Short Term Investments | $11,030,020 | $2,832,931 | $4,602,566 | $350,978 |
| Cash And Cash Equivalents | $6,346,921 | $2,832,931 | $4,602,566 | $350,978 |
| Cash Financial | $6,346,921 | $2,832,931 | $4,602,566 | $350,978 |
| Receivables | - | $0 | $11,862 | $0 |
| Current Deferred Assets | - | - | $0 | $143,427 |
| Other Receivables | - | - | $11,862 | - |
| Non Current Prepaid Assets | - | - | - | $0 |
| Debt | ||||
| Total Debt | - | $0 | $5,061 | $491,231 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $84,267 |
| Current Debt And Capital Lease Obligation | - | - | $5,061 | $406,964 |
| Current Debt | - | - | - | $133,062 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $702,068 | $723,349 | $558,097 | $1,454,306 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $84,267 |
| Current Liabilities | $702,068 | $723,349 | $558,097 | $1,370,039 |
| Payables And Accrued Expenses | $702,068 | $723,349 | $553,036 | $963,075 |
| Payables | $702,068 | $723,349 | $538,564 | $905,554 |
| Accounts Payable | $129,203 | $723,349 | $538,564 | $789,204 |
| Interest Payable | - | $0 | $14,472 | $34,987 |
| Equity | ||||
| Common Stock Equity | $10,391,537 | $2,199,750 | $4,374,346 | $-596,232 |
| Total Equity Gross Minority Interest | $10,391,537 | $2,199,750 | $4,374,346 | $-596,232 |
| Stockholders Equity | $10,391,537 | $2,199,750 | $4,374,346 | $-596,232 |
| Retained Earnings | $-39,580,206 | $-29,137,721 | $-21,285,062 | $-9,302,719 |
| Other | ||||
| Ordinary Shares Number | $41,938,587 | $16,560,852 | $14,780,885 | $14,745,170 |
| Share Issued | $41,938,587 | $16,560,852 | $14,780,885 | $14,745,170 |
| Tangible Book Value | $10,391,537 | $2,199,750 | $4,374,346 | $-596,232 |
| Invested Capital | $10,391,537 | $2,199,750 | $4,374,346 | $-463,170 |
| Working Capital | $10,356,098 | $2,164,311 | $4,300,133 | $-875,634 |
| Total Capitalization | $10,391,537 | $2,199,750 | $4,374,346 | $-596,232 |
| Additional Paid In Capital | $49,967,549 | $31,335,815 | $25,657,930 | $8,699,830 |
| Capital Stock | $4,194 | $1,656 | $1,478 | $6,657 |
| Common Stock | $4,194 | $1,656 | $1,478 | $6,657 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Dueto Related Parties Current | $572,865 | $0 | $0 | $116,350 |
| Duefrom Related Parties Non Current | $35,439 | $35,439 | $69,152 | $0 |
| Other Short Term Investments | $4,683,099 | $0 | - | - |
| Capital Lease Obligations | - | $0 | $5,061 | $358,169 |
| Current Capital Lease Obligation | - | $0 | $5,061 | $273,902 |
| Current Accrued Expenses | - | $0 | $14,472 | $57,521 |
| Net PPE | - | $0 | $5,061 | $363,669 |
| Gross PPE | - | $0 | $5,061 | $363,669 |
| Long Term Capital Lease Obligation | - | - | $0 | $84,267 |
| Line Of Credit | - | - | $0 | $133,062 |
| Other Properties | - | - | $5,061 | $363,669 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-4,661,669 | $-5,560,606 | $-4,532,403 | $-5,604,759 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,661,669 | $-5,560,606 | $-4,532,403 | $-5,604,759 |
| Cash Flow From Continuing Operating Activities | $-4,661,669 | $-5,560,606 | $-4,532,403 | $-5,604,759 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $7,006,982 | $3,608,555 | $7,704,279 | $2,904,000 |
| Financing Cash Flow | $8,175,659 | $3,790,971 | $8,783,991 | $3,146,185 |
| Cash Flow From Continuing Financing Activities | $8,175,659 | $3,790,971 | $8,783,991 | $3,146,185 |
| Net Other Financing Charges | $-292,470 | $182,416 | $74,275 | $402,185 |
| Net Common Stock Issuance | $7,006,982 | $3,608,555 | $7,704,279 | $2,904,000 |
| Common Stock Issuance | $7,006,982 | $3,608,555 | $7,704,279 | $2,904,000 |
| Other | ||||
| Issuance Of Debt | $572,865 | $0 | $2,147,920 | $0 |
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | - |
| End Cash Position | $6,346,921 | $2,832,931 | $4,602,566 | $350,978 |
| Beginning Cash Position | $2,832,931 | $4,602,566 | $350,978 | $2,809,552 |
| Changes In Cash | $3,513,990 | $-1,769,635 | $4,251,588 | $-2,458,574 |
| Proceeds From Stock Option Exercised | $888,282 | $0 | - | - |
| Net Issuance Payments Of Debt | $572,865 | $0 | $1,005,437 | $-160,000 |
| Net Long Term Debt Issuance | $572,865 | $0 | - | - |
| Long Term Debt Issuance | $572,865 | $0 | - | - |
| Change In Working Capital | $-567,563 | $371,248 | $-639,688 | $146,581 |
| Change In Payables And Accrued Expense | $-594,146 | $170,313 | $-389,524 | $152,081 |
| Change In Accrued Expense | $0 | $-14,472 | $0 | - |
| Change In Interest Payable | $0 | $-14,472 | $0 | - |
| Change In Payable | $-594,146 | $184,785 | $-389,524 | - |
| Change In Account Payable | $-594,146 | $184,785 | $-389,524 | - |
| Change In Prepaid Assets | $26,583 | $189,073 | $-243,802 | $0 |
| Change In Receivables | $0 | $11,862 | $-11,862 | $0 |
| Stock Based Compensation | $6,313,167 | $1,920,805 | $2,550,946 | $1,296,600 |
| Unrealized Gain Loss On Investment Securities | $35,212 | $0 | - | - |
| Net Income From Continuing Operations | $-10,442,485 | $-7,852,659 | $-11,982,343 | $-7,058,190 |
| Repayment Of Debt | - | $0 | $-1,142,483 | $-160,000 |
| Net Short Term Debt Issuance | - | $0 | $1,005,437 | $-160,000 |
| Short Term Debt Payments | - | $0 | $-1,142,483 | $-160,000 |
| Short Term Debt Issuance | - | $0 | $2,147,920 | $0 |
| Change In Other Current Assets | - | $0 | $5,500 | $-5,500 |
| Changes In Account Receivables | - | $11,862 | $-11,862 | $0 |
| Change In Other Current Liabilities | - | - | $1,100,096 | $0 |
| Other Non Cash Items | - | - | $5,538,682 | $10,250 |
Fetched: 2026-06-24